Calcium isotope marker technology shows promise for early osteoporosis detection
German diagnostic company osteolabs GmbH has published groundbreaking real-world evidence data from nearly 3,000 patient samples, demonstrating the potential of their proprietary Calcium Isotope Marker (CIM) technology in early osteoporosis risk assessment. The study, published in the journal Bone, [1] marks a significant advancement in the field of metabolic bone disease diagnostics.

